Cancer & Medical Marijuana: Pennsylvania & West Virginia Qualifying Condition Guide

Cancer refers to a broad group of diseases characterized by the uncontrolled growth and spread of abnormal cells. When these cells invade surrounding tissues or spread to distant organs (metastasis), they can impair normal bodily functions and become life-threatening.

Major Cancer Types

• Carcinomas: The most common category, arising from epithelial cells in the skin, lungs, breasts, pancreas, and other organs.
• Lymphomas: Cancers of the lymphatic system, including Hodgkin’s and non-Hodgkin’s lymphoma.
• Leukemias: Cancers of blood-forming tissues, primarily affecting the bone marrow and bloodstream.
• Sarcomas: Cancers of connective tissues including bone, muscle, fat, and cartilage.
• Melanoma: Cancer arising from pigment-producing cells in the skin.
• Brain & CNS Cancers: Tumors originating in the brain or central nervous system.
• Germ Cell Tumors & Others: Including ovarian, testicular, and other less common cancer types.

BOOK NOW

Both Pennsylvania and West Virginia recognize a broad range of cancer diagnoses and cancer-treatment-related conditions as qualifying for medical marijuana certification. These include:

• All primary cancer diagnoses (Carcinoma, Blastoma, Lymphoma, Leukemia, Sarcoma, Melanoma, Neoplasm, Malignant Tumors)
• Bile Duct Type Liver Cancer / Hepatocellular Cancer
• Blood Cancer / Hematopoietic Cancer
• Bone and Muscle Sarcoma
• Brain and Nervous System Cancer
• Breast Cancer
• Carcinoid Tumors
• Endocrine System Cancer
• Eye Cancer
• Gastrointestinal Cancer
• Genitourinary and Gynecologic Cancer / Ovarian Cancer
• Germ Cell Tumor
• Head and Neck Cancer
• Lung Cancer
• Skin Cancer
• Thoracic and Respiratory Cancer
• Cancer of an Unspecified Site (Primary)
• Chemotherapy Illness
• Neoplastic-Related Fatigue
• Radiation Sickness
• Remission (including patients in active remission from cancer)
• Lasting Post-Procedural Pain or Other Symptoms

Patients in remission and those experiencing lasting effects from cancer treatment are explicitly recognized as qualifying. If you are unsure whether your specific diagnosis or treatment-related condition qualifies, contact our team for guidance.

BOOK NOW

The role of cannabinoids in cancer care is an active area of research. The evidence base is most developed for specific symptom management applications — particularly chemotherapy-induced nausea and vomiting — where FDA-approved cannabinoid medications exist. For other symptoms, evidence ranges from preliminary to uncertain. Importantly, there is no established clinical evidence that cannabis treats, cures, or slows the progression of any cancer in humans. This section summarizes the current state of the research honestly and without overstatement. It does not constitute medical advice.

1. Chemotherapy-Induced Nausea & Vomiting (CINV): The Strongest Evidence Base

This is the area where cannabinoid evidence is most robust and where FDA-approved treatments exist. The synthetic cannabinoids dronabinol (Marinol/Syndros) and nabilone (Cesamet) are FDA-approved for chemotherapy-induced nausea and vomiting in patients who have not responded to standard antiemetic therapy. Both are oral THC derivatives and are recognized in ASCO and NCCN clinical guidelines as salvage antiemetics for refractory CINV.

The 2024 American Society of Clinical Oncology (ASCO) guideline on cannabis and cannabinoids in adults with cancer — based on 13 systematic reviews and five additional primary studies — concluded that dronabinol, nabilone, or a quality-controlled oral 1:1 THC:CBD product may be offered to patients with refractory nausea or vomiting who have already received standard antiemetic prophylaxis. ASCO notes that the evidence for adding cannabinoids to modern antiemetic regimens is suggestive but that uncertainty remains, as most CINV studies predate current triple- and quadruple-prophylaxis protocols.

2. Pain Management: Uncertain but Studied

Cancer-related pain is among the most commonly reported reasons patients seek medical cannabis. A 2021 systematic review and meta-analysis published in the BMJ examined 32 randomized trials (5,174 patients) of medical cannabis or cannabinoids for chronic pain, including four trials focused specifically on cancer pain. Results across cancer pain trials were mixed and evidence quality was rated as low to very low. The 2024 ASCO guideline concluded that the effects of cannabis and cannabinoids on cancer pain “remain uncertain and warrant additional research.” Cannabis is not a replacement for established cancer pain management protocols, including opioid therapy when clinically indicated.

3. Appetite Loss & Cachexia: Limited Evidence

Cancer-related anorexia and cachexia (unintended weight loss and muscle wasting) are serious quality-of-life concerns. The 2024 ASCO guideline reviewed four RCTs of cannabinoids for cachexia outcomes. It found that cannabinoids did not produce a statistically significant effect on appetite and that two RCTs showed no weight benefit. ASCO’s 2020 cachexia guideline issued a weak recommendation against cannabinoids for treating cachexia in adults with advanced cancer. Note that dronabinol holds an FDA approval for anorexia in AIDS patients — not specifically for cancer-related cachexia.

4. Neuropathy: An Area of Patient Interest with Limited Trial Data

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often persistent complication affecting sensation, balance, and quality of life. Patients frequently report interest in cannabis for neuropathic symptoms. While cannabis has been studied for neuropathic pain broadly, clinical trial data specific to CIPN remain limited. The 2024 ASCO guideline does not make a specific recommendation for cannabis in CIPN due to insufficient evidence. Patients experiencing neuropathy should discuss all available treatment options with their oncologist.

5. Anti-Tumor Effects: Preclinical Only — Not Established in Humans

Some preclinical studies conducted in laboratory cell lines and animal models have examined whether cannabinoids may have anti-tumor properties, including the ability to induce cancer cell death (apoptosis) or inhibit tumor growth. These are early-stage, laboratory-based findings. As of 2025, there are no completed human clinical trials demonstrating that cannabis or any cannabinoid product treats cancer or slows tumor progression in human patients. Patients should not delay, replace, or discontinue evidence-based cancer treatments based on preclinical findings. Any interest in this area of research should be discussed with an oncologist.

6. Patient-Reported Use & Quality of Life

A 2024 systematic review of 27 observational studies of cannabis use among U.S. cancer patients and survivors found that pain, nausea, appetite loss, anxiety, and sleep disturbance were the primary symptoms driving cannabis use. The review noted that short- and long-term cannabis use may also carry adverse neuropsychological effects that oncologists should evaluate on an individual basis.

BOOK NOW

The following peer-reviewed publications, clinical guidelines, and regulatory sources informed the research summary above. All sources are publicly accessible. No source should be interpreted as establishing medical cannabis as a cancer treatment.